Do Back-to-Back Approvals Make This Biotech Stock a Buy Now?
In the span of one month, the number of gene therapies approved in the U.S. to treat inherited diseases doubled from two to four. Both new therapies are from the same company, bluebird bio (NASDAQ: BLUE).
The stock has risen significantly since the beginning of August, but it still seems awfully low for a biotech with two brand new FDA-approved treatments to sell. At recent prices, bluebird bio still sports a minuscule market cap of about $530 million.
Is it time to buy this overlooked biotech stock or should investors remain cautious?
Source Fool.com
